{
    "topic": "healthcare",
    "source": "Reuters",
    "bias": 1,
    "url": "https://www.reuters.com/article/us-usa-trump-drugpricing/trump-assails-high-drug-prices-avoids-direct-hit-on-industry-idUSKBN1IC2C0",
    "title": "Trump assails high drug prices, avoids direct hit on industry",
    "date": "2018-05-11",
    "authors": "Yasmeen Abutaleb",
    "content": "WASHINGTON ( \u2588\u2588\u2588 ) - U.S. President Donald Trump on Friday blasted drugmakers and healthcare \u201c middlemen \u201d for making prescription medicines unaffordable for Americans , but healthcare stocks rose as his administration avoided aggressive direct measures to cut prices .\nTrump made the remarks at the White House Rose Garden in a speech to introduce what he called \u201c the most sweeping action in history \u201d to lower drug prices . The effort comes as a growing number of Americans struggle with the cost of their medications , and cite healthcare concerns as a top priority for Washington ahead of congressional elections in November .\nTrump said his administration would take aim at the \u201c middlemen \u201d in the drug industry who became \u201c very , very rich , \u201d an apparent reference to health insurers and pharmacy benefit managers ( PBMs ) . He also said the pharmaceutical industry is making an \u201c absolute fortune \u201d at the expense of American taxpayers .\n\u201c Everyone involved in the broken system - the drugmakers , insurance companies , distributors , pharmacy benefit managers , and many others - contribute to the problem , \u201d Trump said .\nTrump campaigned on lowering prescription drug prices ahead of the 2016 presidential election , even accusing drugmakers of \u201c getting away with murder. \u201d Healthcare investors had braced for months for more direct attempts to regulate U.S. prices that would cut into industry profits .\nBut Trump has since abandoned ideas to lower drug costs he supported during the campaign , including allowing the government \u2019 s Medicare plan for older Americans to negotiate prices directly with drugmakers , and enabling U.S. consumers to import lower-cost medicines from other countries .\nOn Friday , Trump \u2019 s senior health officials outlined more modest policy proposals to introduce more competition among drugmakers and pass on savings to consumers .\nCritics said the policies pointed to the influence the pharmaceutical industry wields with the administration .\n\u201c I think very expensive champagne will be popping in drug company boardrooms across the country tonight , \u201d said Democratic Representative Elijah Cummings .\nSenator Ron Wyden , also a Democrat , said the proposals \u201c amount to asking drug companies nicely to lower their prices with zero accountability . \u201d\nShares of major drugmakers , insurers and PBMs rose after the speech . The S & P 500 healthcare index .SPXHC , a broad gauge of large healthcare stocks , closed up 1.5 percent , its biggest single-day percentage gain in a month .\nHealth and Human Services Secretary Alex Azar listens as U.S. President Donald Trump delivers a speech about lowering prescription drug prices from the Rose Garden at the White House in Washington , U.S. , May 11 , 2018 . \u2588\u2588\u2588/Jonathan Ernst\n\u201c The plan was a lot less aggressive than investors expected , \u201d wrote Alex Arfaei , analyst at BMO Capital Markets .\nTrump also placed blame on foreign governments , saying they \u201c extort unreasonably low prices \u201d from U.S. drugmakers , forcing companies to charge more in this country .\n\u201c America will not be cheated any longer , and especially will not be cheated by foreign countries , \u201d he said , adding that he has instructed the U.S. Trade Representative to make the issue a top priority with trading partners .\nAs the speech was underway , the Department of Health and Human Services released what it called a blueprint titled \u201c American Patients First \u201d with details of its plan .\nIt said near-term actions would include giving commercial plans that administer Medicare Part D prescription drug benefits for seniors more power to negotiate prices with drugmakers . Federal health plans would also test ways to pay for drugs based on their effectiveness .\nThe U.S. Food and Drug Administration would evaluate requiring drugmakers to include the list prices they set on medicines in their advertising . Drugmakers argue that list prices do not reflect actual cost after discounts and rebates .\nSome of the administration \u2019 s longer-term priorities include restricting use of rebates , creating incentives for drugmakers to lower list prices , and investigating tools to address foreign government practices that it said could be harming innovation and driving up U.S. prices .\n\u201c There \u2019 s not a big proposal here that is going to make a huge difference . There are a bunch of smaller technical changes , \u201d said Sam Richardson , Associate Professor of Economics at Boston College .\nRegarding forcing other countries to pay more for drugs , Richardson said : \u201c We don \u2019 t really have the policy levers to get that to happen . \u201d\nHealth and Human Services Secretary Alex Azar , a former pharmaceutical company executive , said many of the actions the government was considering would not require approval by Congress and could take place through executive action within months . He said it would take years to restructure the U.S. drug system .\nTrump also blasted the pharmaceutical and insurance industries for spending hundreds of millions of dollars on lobbying to \u201c protect the status quo . \u201d\nHis remarks follow a renewed focus on the influence of the drugmaker lobby , which spends the most of any lobbying group in Washington .\nEarlier this week , Swiss drugmaker Novartis ( NOVN.S ) admitted it paid $ 1.2 million to a consulting firm created by Trump lawyer Michael Cohen .",
    "content_original": "WASHINGTON (Reuters) - U.S. President Donald Trump on Friday blasted drugmakers and healthcare \u201cmiddlemen\u201d for making prescription medicines unaffordable for Americans, but healthcare stocks rose as his administration avoided aggressive direct measures to cut prices.\n\nTrump made the remarks at the White House Rose Garden in a speech to introduce what he called \u201cthe most sweeping action in history\u201d to lower drug prices. The effort comes as a growing number of Americans struggle with the cost of their medications, and cite healthcare concerns as a top priority for Washington ahead of congressional elections in November.\n\nTrump said his administration would take aim at the \u201cmiddlemen\u201d in the drug industry who became \u201cvery, very rich,\u201d an apparent reference to health insurers and pharmacy benefit managers (PBMs). He also said the pharmaceutical industry is making an \u201cabsolute fortune\u201d at the expense of American taxpayers.\n\n\u201cEveryone involved in the broken system - the drugmakers, insurance companies, distributors, pharmacy benefit managers, and many others - contribute to the problem,\u201d Trump said.\n\nTrump campaigned on lowering prescription drug prices ahead of the 2016 presidential election, even accusing drugmakers of \u201cgetting away with murder.\u201d Healthcare investors had braced for months for more direct attempts to regulate U.S. prices that would cut into industry profits.\n\nBut Trump has since abandoned ideas to lower drug costs he supported during the campaign, including allowing the government\u2019s Medicare plan for older Americans to negotiate prices directly with drugmakers, and enabling U.S. consumers to import lower-cost medicines from other countries.\n\nOn Friday, Trump\u2019s senior health officials outlined more modest policy proposals to introduce more competition among drugmakers and pass on savings to consumers.\n\nCritics said the policies pointed to the influence the pharmaceutical industry wields with the administration.\n\n\u201cI think very expensive champagne will be popping in drug company boardrooms across the country tonight,\u201d said Democratic Representative Elijah Cummings.\n\nSenator Ron Wyden, also a Democrat, said the proposals \u201camount to asking drug companies nicely to lower their prices with zero accountability.\u201d\n\nShares of major drugmakers, insurers and PBMs rose after the speech. The S&P 500 healthcare index .SPXHC, a broad gauge of large healthcare stocks, closed up 1.5 percent, its biggest single-day percentage gain in a month.\n\nHealth and Human Services Secretary Alex Azar listens as U.S. President Donald Trump delivers a speech about lowering prescription drug prices from the Rose Garden at the White House in Washington, U.S., May 11, 2018. REUTERS/Jonathan Ernst\n\n\u201cThe plan was a lot less aggressive than investors expected,\u201d wrote Alex Arfaei, analyst at BMO Capital Markets.\n\n\u2018AMERICAN PATIENTS FIRST\u2019\n\nTrump also placed blame on foreign governments, saying they \u201cextort unreasonably low prices\u201d from U.S. drugmakers, forcing companies to charge more in this country.\n\n\u201cAmerica will not be cheated any longer, and especially will not be cheated by foreign countries,\u201d he said, adding that he has instructed the U.S. Trade Representative to make the issue a top priority with trading partners.\n\nAs the speech was underway, the Department of Health and Human Services released what it called a blueprint titled \u201cAmerican Patients First\u201d with details of its plan.\n\nIt said near-term actions would include giving commercial plans that administer Medicare Part D prescription drug benefits for seniors more power to negotiate prices with drugmakers. Federal health plans would also test ways to pay for drugs based on their effectiveness.\n\nThe U.S. Food and Drug Administration would evaluate requiring drugmakers to include the list prices they set on medicines in their advertising. Drugmakers argue that list prices do not reflect actual cost after discounts and rebates.\n\nSome of the administration\u2019s longer-term priorities include restricting use of rebates, creating incentives for drugmakers to lower list prices, and investigating tools to address foreign government practices that it said could be harming innovation and driving up U.S. prices.\n\n\u201cThere\u2019s not a big proposal here that is going to make a huge difference. There are a bunch of smaller technical changes,\u201d said Sam Richardson, Associate Professor of Economics at Boston College.\n\nRegarding forcing other countries to pay more for drugs, Richardson said: \u201cWe don\u2019t really have the policy levers to get that to happen.\u201d\n\nHealth and Human Services Secretary Alex Azar, a former pharmaceutical company executive, said many of the actions the government was considering would not require approval by Congress and could take place through executive action within months. He said it would take years to restructure the U.S. drug system.\n\nSlideshow (6 Images)\n\nTrump also blasted the pharmaceutical and insurance industries for spending hundreds of millions of dollars on lobbying to \u201cprotect the status quo.\u201d\n\nHis remarks follow a renewed focus on the influence of the drugmaker lobby, which spends the most of any lobbying group in Washington.\n\nEarlier this week, Swiss drugmaker Novartis (NOVN.S) admitted it paid $1.2 million to a consulting firm created by Trump lawyer Michael Cohen.",
    "source_url": "www.reuters.com",
    "bias_text": "center",
    "ID": "7lIzDVErGu1bH3gY"
}